Skip to main content

Advertisement

Fig. 1 | Journal of Medical Case Reports

Fig. 1

From: Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report

Fig. 1

Computed tomographic scan showing response with BRAF inhibitor in a patient with stage IV ameloblastoma. Target lesions were measured before treatment (6 December 2016) and 26 months after treatment (7 February 2018), respectively, at 56 mm (a) and 36 mm (b) in the left apical lower lobe and 64 mm (c) and 43 mm (d) in the right apical lower lobe. Reduction in tumor mass is shown. The red lines denotes the length of lesions taken into account respectively 56 mm for a, 36 mm for b, 64 mm for c and 43 mm for d

Back to article page